For the incredibly small amount that I know, it looks like a game changer. (Like everything else, though, there's a long road from theory to practice. Implementation is going be very tough)
For the incredibly small amount that I know, it looks like a game changer. (Like everything else, though, there's a long road from theory to practice. Implementation is going be very tough)
https://www.nature.com/articles/d41586-019-03072-8
If this immunotherapy gets developed further, the next generations of humanity may look at cancer in the same way that we look upon bacterial diseases: unpleasant, the threat of treatment resistance is there, but not the fearsome serial killer that they used to be.
in such 3world country, misuse/overuse of antibiotic are make for development of resistant. then poor sanatation are make for it easy for to spread to other persons. https://wwwnc.cdc.gov/eid/article/5/1/99-0103_article
"Developing Nations" or "Developing World" is better.
"Third world" contributes to exactly the kinds of stereotypes that this comment reinforces — the backwardness of poor countries, where doctors don't know better, science is ignored, etc. It's just not accurate; medical knowledge and competence is on the rise all over the world, among both professionals and volunteers.
i have not in previous heard it "offensive" and am not changing because some person sayes it. i have been to many nation, those i call "third world" are backward. improvement you describe make them moving away from third world, not make term wrong, this is move to second then to first. i will not call different word because somebody say so.
Those treatment resistances are quite different. Resistant bacteria spread to other people, while cancer is almost always limited to a single patient. So it the treatment works for a certain fraction of cancers, it'll stay at that level, unlike bacteria which become increasingly resistant over time.
(I guess that in the very long term that might not be true, since natural cancer resistance will offer less of an evolutionary advantage. But that assumes that humanity will remain in a similar state as currently, which seems unlikely.)
Cancers are very patient-specific, and the main threat with immunotherapy is that the targeted cancer adapts quickly enough to escape the immune system again.
(I'm just an interested party and don't have any formal training on the subject.) I'm sure there are technical terms for it, but from what I've read the lack of regulatory features in the replication process of cancer cells tends to accumulate more mutations and genetic damage through each generation. PARP-inhibitors, for example, help fight cancer by suppressing DNA repair enzymes and letting the cancer cells get into non-viable states more often than healthy tissue.
In general though, this genetic entropy/volatility creates a scenario where adaptations can happen quite quickly.